Clinical trial
Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage…
NCT00402883 · SCRI Development Innovations, LLC, Other · Terminated
Key facts
| NCT number | NCT00402883 |
|---|---|
| Title | Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer |
| Official title | A Phase II Study of Pemetrexed/Carboplatin/Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer |
| Lead sponsor | SCRI Development Innovations, LLC, Other |
| Collaborators | Genentech, Inc. Industry Eli Lilly and Company |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug, Other, Procedure |
| Interventions | Bevacizumab, Pemetrexed, Radiotherapy, Folic Acid, vitamin B12, carboplatin |
| Enrollment | 5 |
| Start date | Nov 1, 2006 |
| Primary completion | Jan 1, 2009 |
| Completion | Jan 1, 2009 |
| First posted | Nov 22, 2006 |
| Last update posted | Nov 9, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: